Aus­tralian bio­phar­ma buys ra­dioiso­tope pro­duc­er in its next step to ‘dou­ble’ ca­pac­i­ty in 2024 

Telix Phar­ma­ceu­ti­cals is still on its ra­dio­phar­ma man­u­fac­tur­ing shop­ping spree. The Aus­tralian biotech is buy­ing com­mer­cial-stage ra­dioiso­tope pro­duc­er ARTMS for $57.5 mil­lion up­front, with an ex­tra $24.5 mil­lion for fu­ture mile­stones.

Just last week, Telix al­so an­nounced it bought Texas-based ra­dio­phar­ma com­pa­ny IsoTher­a­peu­tics for $8 mil­lion up­front. For 2023, Telix tout­ed it dou­bled its in-house man­u­fac­tur­ing, with plans to dou­ble again in 2024.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.